Drug Discovery@nature.com 11 April 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 11 April 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement   Partnerships that drive high impact open science  Nature Partner Journals is a new series of online open access journals published in collaboration with world-renowned international partners. Each partnership in the portfolio brings together strong editorial leadership with world-class publication systems to deliver high-quality, peer-reviewed original research.     News Top NIH stem-cell programme closes doi:10.1038/508157a Director resigns as just one clinical-trial award is made. Full Text Regulators adopt more orphan drugs doi:10.1038/508016a Agencies face rising applications for rare-disease therapies resulting from increasingly precise disease definitions. Full Text Cancer treatment: The killer within doi:10.1038/508024a The immune system can be a powerful weapon against cancer — but researchers are still grappling with how to control it. Full Text Report urges controversial 'delinkage' to foster new antibiotics doi:10.1038/nm0414-320 A UK thinktank argues that separating antibiotic revenues from sales could kickstart development efforts. Full Text Analysis Top Critical mass in diabetes doi:10.1038/scibx.2014.360 A new target, STK4, can increase β cell mass and may provide an alternative to invasive islet cell transplants to treat diabetes. Full Text The COPD pipeline doi:10.1038/nrd4254 Therapeutic approaches to treat chronic obstructive pulmonary disease (COPD) are varied, and recent approvals have diversified treatment options. Full Text Research Highlights Top Antibacterial drugs: Redesigned antibiotic combats drug-resistant tuberculosis doi:10.1038/nrd4287 A novel class of anti-TB agents, called spectinamides, has shown activity against multidrug-resistant TB. Full Text Cancer: Live screening of immunotherapy targets doi:10.1038/nrd4289 A new study has outlined an approach for the in vivo discovery of immunotherapy targets in melanoma using RNA interference technology. Full Text Neurodegenerative disease: Searching for the weak spots doi:10.1038/nrd4284 Matrix metalloproteinase 9 could be a promising therapeutic target for amyotrophic lateral sclerosis. Full Text Research & Reviews Top Aquaporins: important but elusive drug targets doi:10.1038/nrd4226 The authors discuss the therapeutic potential of targeting aquaporin channels as well as associated challenges, such as the suitability of assay methods. Full Text Targeting the pancreatic β-cell to treat diabetes doi:10.1038/nrd4231 Wagner and colleagues discuss strategies to promote β-cell proliferation, survival and function for the treatment of diabetes, and consider ongoing challenges to drug development efforts that are aimed at targeting this cell population. Full Text Advances in targeting cyclic nucleotide phosphodiesterases doi:10.1038/nrd4228 A review of how recent understanding of the roles of individual cyclic nucleotide phosphodiesterases (PDEs) is aiding the development of more sophisticated strategies to target individual PDE variants. Full Text Pathological pain and the neuroimmune interface doi:10.1038/nri3621 The authors explain how the immune and nervous systems interact to initiate and propagate pain, and discuss the immune components that can be targeted for alleviating pathological pain in patients. Full Text Drug Discovery JOBS of the week Post-Doctoral Research Fellow, Drug Discovery / Project Violet - Optide Fred Hutchinson Cancer Research Center Projects Team Leader ? Drug Development Cancer Research UK Postdoctoral Research Fellow: Medicinal chemistry / chemical biology Massachusetts General Hospital & Harvard Medical School More Science jobs from Drug Discovery EVENT 15th International Conference on Alzheimer?s Drug Discovery 08.09.14 New Jersey, USA More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.